

**TABLE 2.** Cardiovascular and renal outcomes of SGLT-2 inhibitors

	<b>EMPA-REG</b>	<b>CANVAS</b>	<b>DECLARE</b>
Patients with established cv disease	99%	65.6%	40.6%
CV outcomes			
MACE-3	0.86 (0.74 – 0.99)	0.86 (0.75-0.97)	0.93 (0.84 – 1.03)
CV death	0.62 (0.49 – 0.77)	0.87 (0.72-1.06)	0.98 (0.82 – 1.17)
Non-fatal MI	0.87 (0.70 – 1.09)	0.85 (0.69-1.05)	0.89 (0.77 – 1.01)
Non-fatal stroke	1.24 (0.92 – 1.67)	0.90 (0.71-1.15)	1.01 (0.84 – 1.21)
Mortality	0.68 (0.57 – 0.82)	0.87 (0.74-1.11)	0.93 (0.82 – 1.04)
HF hospitalization	0.65 (0.50 – 0.85)	0.67 (0.47-0.77)	0.73 (0.61 – 0.88)
Renal outcomes			
Composite renal outcome	0.61 (0.53 – 0.70)	0.64 (0.46 – 0.88)	0.53 (0.43 – 0.66)
Progression of albuminuria	-	0.73 (0.67–0.79)	
40% reduction in eGFR, renal-replacement therapy, or renal death	-	0.60 (0.47–0.77)	0.53 (0.43–0.66)

\*Data are presented as hazard ratio, 95% confidence intervals

Abbreviations: CV: cardiovascular, MACE: major adverse cardiovascular events, MI: myocardial infraction, HF: heart failure